Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

NCT ID: NCT04575545

Last Updated: 2020-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-31

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Virus-HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV positive patients

Serology test for COVID-19

Intervention Type DIAGNOSTIC_TEST

ELISA test

Patients taking PrEP

Serology test for COVID-19

Intervention Type DIAGNOSTIC_TEST

ELISA test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serology test for COVID-19

ELISA test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged ≥ 18 years
* patients infected by the HIV on treatment
* patients taking PreP (Pre-exposure prophylaxis (PrEP))
* Being affiliated with or benefiting from a social security scheme

Exclusion Criteria

* Subject to a measure for the protection of justice
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hôpital Européen Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrick PHILIBERT

Role: PRINCIPAL_INVESTIGATOR

Hôpital Europeen Marseille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

BENNANI

Marseille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Myriam BENNANI

Role: CONTACT

0413428351

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A02018-31

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Project Engage: Oral PrEP Acceptability
NCT05458765 COMPLETED PHASE2